are under way to reduce its TB burden. This paper is a part of those efforts and examines the epidemiology of TB, progress towards global and regional targets, lessons learned, and ways forward for mitigating the burden of TB in Kiribati.
The national TB programme in Kiribati
The Kiribati NTP uses both passive and active case-finding to identify persons with TB. Active case-finding in Kiribati includes TB contact tracing of household members and immediate neighbouring households of patients found to be smear-positive. It also screens people living with HIV, prisoners, and people with diabetes. In addition, there is a community TB screening programme in villages with a higher than average case notification of TB. The NTP has a dedicated TB laboratory, co-located with the TB Control Centre.
Pulmonary TB (PTB) is diagnosed primarily using sputum smear microscopy, which involves the collection of three sputum specimens. Patients who return a positive smear are registered and enrolled on TB treatment, and those with a negative smear have a chest X-ray and are reviewed by a clinician.
The TB laboratory has recently introduced TB culture, which is requested for (1) patients who have multiple negative sputum smears but clinical and radiological support for a diagnosis of TB, (2) patients with concomitant HIV, (3) patients with a moderate to strong clinical suspicion of HIV/AIDS, but for whom confirmation has not been obtained and there is a moderate to strong suspicion of TB, (4) patients who are still smear-positive at 2 months, (5) paediatric cases where respiratory secretions can be collected, and (6) symptomatic contacts of a known drug-resistant TB case. Respiratory samples from all symptomatic previously treated cases and those with PTB who are smear-positive after 3 months of treatment are sent to the Supranational TB Reference Laboratory in Adelaide, South Australia for culture and drug susceptibility testing (DST). Patients with suspected extrapulmonary TB (EPTB) are diagnosed on the basis of X-ray findings and clinical examination; samples from lymph node and ascitic fluid are occasionally examined for acid-fast bacilli (AFB).
Most TB cases are referred to South Tarawa for diagnosis, as the outer islands do not have laboratory capacity. However, if a patient cannot travel to South Tarawa, and if sputum is able to be collected, the sputum specimens are sent to South Tarawa for analysis. When diagnosed, TB patients receive treatment in South Tarawa for the initial phase of treatment (2 months). The hospital in South Tarawa has a dedicated TB ward, and patients are only hospitalized if clinically indicated. Most TB treatment in Kiribati is through community-based treatment and care. This is for the duration of the initial phase of treatment. Community-based treatment and care involves daily visits by a nurse or community DOT worker (CDW) to supervise TB treatment and monitor for clinical response to treatment and side effects. In South Tarawa, community-based treatment and care involves patients being treated at home, or, if they are in South Tarawa from the outer islands, living temporarily with family members in the South Tarawa community, or in a TB 'maneaba' (a traditional i-Kiribati meeting house).
Methods

Source of data
The WHO Global Tuberculosis Report 2013 was the data source for this analysis. The Kiribati NTP uses all WHO definitions and uses structured recording and reporting mechanisms to capture data from the TB laboratory and the NTP. The Programme reports case notifications (including drug-resistant and HIV-related TB) and treatment outcomes to the WHO on an annual basis and these data are published in the annual WHO global TB reports and as data files on the WHO website. 7, 8 This is actual measured data.
On the other hand, actual measured data on prevalence, incidence, mortality, and case detection are unavailable, and thus estimates are made by the WHO. The details on how these are derived can be found in the global TB reports, scientific publications, and on the WHO website. 7, 9 In brief, incidence is estimated through an expert opinion process facilitated by the WHO and decisions are based on the analysis of TB notification and programmatic data. 7 Prevalence is estimated using incidence and duration estimates. 7 The case detection ratio (CDR) is estimated by dividing the number of TB case notifications by the estimated number of incident cases of TB. Mortality also needs to be estimated by the WHO as Kiribati does not have a national vital registration system with adequate coverage and completeness to provide an accurate estimate. 
Analysis
Data (2000-2012) on case notifications, including drugresistant and HIV-related TB, prevalence, incidence, mortality, and treatment outcomes (2000-2011) were extracted from the WHO global TB reports and data files. 7, 8 For the purpose of better informing the NTP planning and policy, we worked with key members of the NTP to undertake an in-depth analysis and interpretation of these tabulated data. The case notifications included all new and relapse cases. Age-specific case notification rates per 100 000 population were calculated using the age-specific number of pulmonary smear-positive case notifications divided by the age-specific average population for the same period. 10 Prevalence, incidence, mortality, and case detection estimates were compiled from the WHO Global Tuberculosis Report 2013. Treatment outcomes were defined by the WHO as follows: (1) cured: a patient who was initially sputum smear-positive and who was sputum smear-negative in the last month of treatment and on at least one previous occasion; (2) completed treatment: a patient who completed treatment but did not meet the criteria for cure or failure; (3) died: a patient who died from any cause during treatment; (4) failed: a patient who was initially sputum smearpositive and who remained sputum smear-positive at month 5 or later during treatment; and (5) lost to follow-up: a TB patient who did not start treatment or whose treatment was interrupted for two consecutive months or more. 7 The progress made in Kiribati was then assessed against the MDG for TB and the Regional Strategy to Stop Tuberculosis in the Western Pacific 2011-2015 goals. 11, 12 3. Results
Case notifications
Over the 13-year period, Kiribati reported a total of 3863 TB notifications; 3797 (98%) were newly diagnosed and 66 (2%) were relapse cases. 13 The number of notifications increased slightly from 2000 to 2012, with some fluctuations in-between (Table 1 ; Figure 1 ). The case notification rate followed a similar pattern and increased from 304 per 100 000 population in 2000 to 343 in 2012. Of all new TB notifications, 1481 (38%) were pulmonary sputum smear-positive, 948 (25%) were pulmonary sputum smearnegative, and 1268 (33%) were classified as extrapulmonary; the remaining 4% were classified as smear unknown/not done, other new cases, or relapse cases Fifty-two per cent (n = 774) of all new pulmonary smearpositive TB notifications were for males and 8% (n = 121) were for children aged 0-14 years. The number of new notifications of pulmonary smear-positive TB peaked in the 15-24 years age group, and this was consistent for males and females. 13 However, the rate of new notifications was highest in the age group 55-64 years and this was substantially higher in males ( Figure 3 ). For EPTB, there was no clear pattern according to age group; the rate of notifications ranged from 525/100 000 population in the 25-34 years age group to 788/100 000 population in the 65+ years age group (the 0-14 years age group was 727/100 000).
Incidence
The estimated number of incident cases increased between 2000 (310; 95% confidence interval (CI) 250-380) and 2012 2000  82 788  252  304  400  483  310  374  13  16  2001  84 261  189  224  360  427  280  332  11  13  2002  85 799  196  228  380  443  290  338  14  16  2003  87 371  284  325  480  549  340  389  15  17  2004  88 936  310  349  590  663  400  450  15  17  2005  90 468  332  367  680  752  440  486  15  17  2006  91 953  378  411  740  805  470  511  15  16  2007  93 401  334  358  590  632  420  450  16  17  2008  94 832  335  353  590  622  420  443  16  17  2009  96 272  278  289  440  457  350  364  16  17  2010  97 743  286  293  470  481  360  368  16 (Figure 1 ). The incidence rate followed a similar trend.
Prevalence
Estimated prevalence followed a similar trend as incidence (Figure 1) . The estimated number of prevalent cases increased between 2000 (400; 95% CI 140-790) and 2012 (630; 95% CI 270-1100), although this was not significant at the 0.05 level. The estimated number of prevalent cases per 100 000 population followed the same trend.
Mortality
The estimated number and rate of deaths from TB (excluding HIV) was relatively consistent over the 13-year period. There were 196 deaths in total (mean 15.1 deaths/year). The mean mortality rate was 16 deaths per 100 000 population.
Case detection rate (CDR)
The CDR fluctuated from 2000 (81%) to 2005 (75%), and has been stable at approximately 80% since 2006 (Figure 1 ). cases smear-positive after 2 months of treatment. Six of these samples were drug-resistant: three were mono-resistant to streptomycin, two had mono-resistance to rifampin, and one was resistant to isoniazid and rifampin, i.e. multidrug-resistant TB (MDR-TB). Despite treatment, the patient with MDR-TB died. 13 
HIV-associated TB
Treatment outcomes
The total size of the treatment cohort of all TB cases was only available for the years 2004 to 2011; over this period, the proportion of diagnosed patients who commenced treatment was 95%. The majority of TB patients in Kiribati complete treatment and/or are cured (Table 3) . From 2000 to 2011, 89% were successfully treated (i.e., completed treatment and/or were cured). Of smear-positive cases, 94% were successfully treated from 2000 to 2011 -this ranged from 90% in 2003 to 97% in 2004 and 2009. Of re-treatment cases, the mean annual proportion successfully treated was 83%.
Progress towards regional targets
The MDG target for TB is 'to reduce TB incidence by 2015'. In Kiribati, the estimated number of incident cases increased from 310 in 2000 (95% CI 250-380) to 430 in 2012 (95% CI 350-520). When population growth was taken into account through the calculation of incidence rates, there was still an increase, though not to the same extent: 372/100 000 population in 2000 (95% CI 296-456) and 429/100 000 population in 2012 (95% CI 349-517). These results suggest that the MDG target is unlikely to be met by 2015.
The Regional Strategy to Stop Tuberculosis in the Western Pacific 2011-2015 has two overarching targets. The first is to reduce TB prevalence by half by 2015 relative to the level in 2000. The estimated number of prevalent cases of TB in Kiribati in 2000 was 400 (95% CI 140-790); this increased to 630 (95% CI 270-1100) in 2012. Similarly, the prevalence per 100 000 population was 487 (95% CI 174-957) in 2000, and increased to 628 (95% CI 270-1132) in 2012. These trends suggest that this goal is unlikely to be achieved by 2015.
The second target of the regional strategy is to reduce TB mortality by half by 2015, relative to the level in 2000. The estimated number of TB deaths in Kiribati in 2000 was 13 (95% CI 9.3-16), and this increased to 17 in 2012 (95% CI 9.6-26), although the confidence intervals overlap substantially. The rate of TB deaths per 100 000 population was 15 in 2000 (95% CI 11-20) and increased to 17 in 2012 (95% CI 9.5-26). Reducing the number of deaths per year to six or less by 2015 would achieve the target. This is possible, although the number of deaths has been consistent over the past 13 years.
Discussion
At the global level, there has been a reduction in the TB incidence, prevalence, and mortality from 2000 to 2012. 7 However, the estimated TB prevalence and incidence in Kiribati are increasing. This is mirrored by an increase in cases notifications, much of which is due to enhanced TB case-finding efforts and the introduction of liquid culture in recent years. The MDG target for TB and the two overarching targets of the Regional Strategy to Stop Tuberculosis in the Western Pacific 2011-2015 are unlikely to be met in Kiribati by 2015. The estimated CDR was variable between 2000 and 2005, which is likely to be due to changes in practice regarding TB case-finding in Kiribati, and has not improved since 2006. Case notifications and estimated incidence and prevalence of TB have increased slightly since 2000. While these declined for a few years after 2006, they have increased again in recent years. Below, we discuss potential reasons for these trends, explore lessons learned, and make recommendations that we believe will improve progress towards these global and regional targets. -treatment  3  9  8  0  1  0  0  89%  2001  Smear-pos  64  64  56  5  2  1  0  95%  Re-treatment  6  2  2  0  0  0  0  100%  2002  Smear-pos  82  82  71  6  3  2  0  94%  Re-treatment  3  3  1  2  0  0  0  100%  2003  Smear-pos  99  97  73  14  10  0  0  90%  Re-treatment  4  2  2  0  0  0  0  100%  2004  Smear-pos  142  138  124  10  2  1  5  97%  Re-treatment  3  3  2  0  0  1  0  67%  2005  Smear-pos  124  123  76  38  8  0  2  93%  Re-treatment  10  3  3  0  0  0  0  100%  2006  Smear-pos  129  126  77  36  12  0  4  90%  Re-treatment  5  15  3  9  1  0  2  80%  2007  Smear-pos  103  100  79  14  7  0  3  93%  Re-treatment  24  5  5  0  0  0  0  100%  2008  Smear-pos  147  146  136  4  6  0  1  96%  Re-treatment  17  17  9  4  2  0  2  76%  2009  Smear-pos  145  144  121  19  4  0  1  97%  Re-treatment  4  6  5  1  0  0  0  100%  2010  Smear-pos  118  117  103  6  6  2  1  93%  Re-treatment  14  20  5  9  6  0  0  70%  2011  Smear-pos  140  140  103  29  6  1  1  94%  Re-treatment  18  19  4  10  1  0  4  74% a The number of annual re-treatment cases totals more than the number of relapse cases in Table 2 . The category of re-treatment includes TB patients with an outcome of relapse, treatment failed, treatment after loss to follow-up, and other patients who have been treated previously. In some instances there is a difference between the number of notifications and the number in the cohort; these figures reflect those reported to the WHO by member countries and areas, and are usually due to the fact that TB patients notified in any given year may not have their TB treatment outcomes assessed in cohort analysis, for a number of reasons. b Treatment success rate = % cured + % completed.
Risk factors slowing progress
TB risk factors comprise a complex mix of socio-economic conditions, biological risk factors, and opportunities for TB exposure.
14 The key risk factors described in the literature include HIV, a poor diet high in fats and sugars, childhood malnutrition, obesity, smoking, diabetes, alcohol use, indoor air pollution, crowded accommodation, and unemployment. [14] [15] [16] [17] [18] It is clear that a number of these risk factors are present in Kiribati and are likely to be driving the TB epidemic. A recent study assessing the association between TB and diabetes in Kiribati estimated that approximately one quarter of all TB is attributable to diabetes. 19 HIV prevalence is significantly lower in Kiribati than in many areas of the world, and it appears that the epidemic in Kiribati is largely being driven by poverty, poor nutrition, poor living conditions resulting from high population density, diabetes, and smoking.
Rates of diabetes and smoking in Kiribati are among the highest in the Pacific. Thirty percent of men and 27% of women have diabetes. Seventy-four percent of men and 45% of women smoke daily. Forty-five percent of men and 6% of women identify themselves as current drinkers, i.e., those who had consumed alcohol within the past 12 months. Of these, 83% of men and 51% of women consume, on average, 6+ drinks on a drinking day. 20 In addition, 22% of children aged <5 years are underweight -the second-highest proportion in the Pacific. Another confounder is the relatively large proportion of women who have unmet family planning needs, resulting in a high fertility rate (3.9 live-births/woman), a figure that has increased over recent years. 2 Moreover, Kiribati is vulnerable to the effects of climate change. Sea-level rise is an issue of particular concern; in Kiribati, the sea-level is rising at the rate of 3.9 mm per year, which is three times the global average. 23 Over the long term, this will reduce available land, resulting in a further increase in population density.
Lessons learned and recommendations for improving progress
This analysis highlights the unique set of challenges faced in an island setting with a double burden of disease and vulnerability to climate change. On a positive note, testing of TB cases for HIV has increased over recent years, and very few were found to be seropositive. Despite this, further efforts are needed to improve the proportion of TB patients who are tested for HIV, especially those who are at particularly high risk for HIV. MDR-TB is a major challenge for TB control in some areas of the Pacific, such as the Republic of Marshall Islands and Federated States of Micronesia; however, this is not yet a significant public health problem in Kiribati. The majority of TB patients complete treatment and/or are cured, and the good treatment success rates appear to have been achieved through a system of community-based DOT.
Greater focus is needed on identifying people with TB early and preventing TB. The CDR indicates that approximately 20% of TB cases are missed. While this is quite high by global standards, particularly given currently available diagnostics in Kiribati, it should be borne in mind that a large proportion of diagnosed cases are not bacteriologically confirmed, and thus over-diagnosis may be masking a large undiagnosed TB burden. Active methods of TB case detection are required to detect additional cases and detect them early, thereby reducing the opportunity for ongoing transmission of TB in the community. Population-wide as well as targeted behaviour change campaigns are needed to reduce the risk of TB from a range of related risk factors, including smoking, diabetes, alcohol use, and crowded living. This requires a concerted, multi-sector approach.
Surveillance of TB in Kiribati needs to incorporate broader indicators such as smoking, diabetes, alcohol use, and number of people in the household. This will help to validate and/or update the focus of targeted campaigns. People with diabetes should be screened routinely for TB, and TB patients should continue to be screened routinely for diabetes.
Improving diagnostic capacity through the implementation of technologies such as Xpert MTB/RIF should also improve case detection. Behaviour change campaigns should also promote the importance of early testing, and research is needed to explore barriers and facilitators to accessing health care for people with suspected TB, as well as people suspected of diabetes. 
Conclusions
While there have been some successes with TB treatment in Kiribati over the past 13 years, case notifications and estimated incidence and prevalence of TB have increased. The TB-related MDG and the high order goals of the regional strategy to stop TB are unlikely to be met for Kiribati by 2015. A chief reason for this is likely to be the complex mix of TB risk factors present in Kiribati, including relative poverty, smoking, diabetes, alcohol use, crowded living, high unemployment, and stress levels associated with rising sea levels, causing loss of their homeland. Greater focus is needed on preventing TB, and particularly on reducing people's vulnerability to it. Further research is needed to better understand the risk factors and health care-seeking behaviours related to TB in Kiribati.
